摘要
目的:分析慢性阻塞性肺疾病急性加重期(AECOPD)早期使用低分子肝素的临床疗效。方法:选取郑州大学第一附属医院2021年6月至2022年6月收治的100例AECOPD患者,将接受常规方案治疗的50例患者纳入对照组,将早期使用低分子肝素联合常规方案治疗的50例患者纳入观察组。比较两组患者呼吸状况、血常规、炎症因子、血管内皮功能和血液流变学相关指标情况及治疗相关不良反应。结果:治疗后,观察组患者中性粒细胞/淋巴细胞比率、血小板/淋巴细胞比率均低于对照组,差异具有统计学意义(P<0.05);治疗后,观察组患者的白细胞介素-6、肿瘤坏死因子-α水平均低于对照组,差异具有统计学意义(P<0.05);治疗后,观察组患者内皮素-1水平低于对照组,一氧化氮水平高于对照组,差异具有统计学意义(P<0.05);治疗后,观察组患者红细胞比容、血浆黏度及全血高切黏度水平均低于对照组,差异具有统计学意义(P<0.05);治疗后,观察组患者呼吸困难评分低于对照组,差异具有统计学意义(P<0.05);两组患者均无不良反应发生。结论:AECOPD患者应尽早使用低分子肝素治疗,有助于缓解高凝血状态,保护血管内皮功能,控制机体炎症反应程度。
Objective To analyze the clinical efficacy of early use of low molecular weight heparin in acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Methods A total of 100 patients with AECOPD admitted to the First Affiliated Hospital of Zhengzhou University from June 2021 to June 2022 were selected,fifty patients receiving conventional treatment were included in the control group,and fifty patients receiving early treatment with low molecular weight heparin combined with conventional treatment were included in the observation group.Respiratory status,blood routine,inflammatory factors,vascular endothelial function and hemorheology related indexes and treatment-related adverse reactions were compared between the two groups.Results After treatment,the ratios of neutrophil/lymphocyte and platelet/lymphocyte in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the levels of interleukin-6 and tumor necrosis factor-αin the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the level of endothelin-1 in the observation group was lower than that of the control group,and the level of nitric oxide was higher than that of the control group,the differences were statistically significant(P<0.05).After treatment,the levels of hematocrit,plasma viscosity and whole blood high tangential viscosity in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).After treatment,the dyspnea score of the observation group was lower than that of the control group,and the difference was statistically significant(P<0.05).No adverse reactions occurred in the two groups.Conclusion Patients with AECOPD should be treated with low molecular weight heparin as early as possible,which is helpful to relieve hypercoagulability,protect vascular endothelial function and control the degree of inflammation in the body.
作者
周芮伊
崔嬿嬿
ZHOU Ruiyi;CUI Yanyan(The First Affiliated Hospital of Zhengzhou University,Henan Zhengzhou 450000)
出处
《深圳中西医结合杂志》
2023年第15期19-22,共4页
Shenzhen Journal of Integrated Traditional Chinese and Western Medicine
关键词
慢性阻塞性肺疾病
急性加重期
低分子肝素
Chronic obstructive pulmonary disease
Acute exacerbation stage
Low molecular weight heparin
